An overview of tuberculosis plant-derived vaccines

Tuberculosis (TB) is leading fatal infectious disease to which the current BCG vaccine has questionable efficacy in adults. Thus, the development of improved vaccines against TB is needed. In addition, decreasing the cost of vaccine formulations is required for broader vaccination coverage through global vaccination programs. In this regard, the use of plants as biofactories and delivery vehicles of TB vaccines has been researched over the last decade. These studies are systematically analyzed in the present review and placed in perspective. It is considered that substantial preclinical trials are still required to address improvements in expression levels as well as immunological data. Approaches for testing additional antigenic configurations with higher yields and improved immunogenic properties are also discussed. © 2015 Informa UK, Ltd.

cellular immunity; inflammation; Mycobacterium tuberculosis; oral immunization; subunit vaccine; vaccine cost BCG vaccine; cholera toxin B subunit; culture filtrate protein 10; early secretory antigenic target 6; unclassified drug; virus vector; vpm 1002; BCG vaccine; edible vaccine; recombinant vaccine; subunit vaccine; antigen antibody complex; Arabidopsis thaliana; biomass; carrot; chloroplast; human; immunization; lettuce; Nicotiana benthamiana; nonhuman; phase 1 clinical trial (topic); phase 2 clinical trial (topic); plant cell; potato; priority journal; protein expression; Review; tuberculosis; vaccination; animal; drug development; drug screening; genetics; immunology; metabolism; oral drug administration; transgenic plant; trends; Administration, Oral; Animals; Drug Discovery; Drug Evaluation, Preclinical; Plants, Genetically Modified; Tuberculosis Vaccines; Vaccines, Edible; Vaccines, Subunit; Vaccines, Synthetic

VIVO